Adiponectin is Protective against Oxidative Stress Induced Cytotoxicity in Amyloid-Beta Neurotoxicity

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Chan, Koon Ho ^a   Lam, Karen Siu Ling ^a   Cheng, On Yin ^a   Kwan, Jason Shing Cheong ^a   Ho, Philip Wing Lok ^a   Cheng, Kenneth King Yip ^a   Chung, Sookja Kim ^a   Ho, Jessica Wing Man ^a   Guo, Vivian Yawei ^a   Xu, Almin ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; LEUCINE ZIPPER PROTEIN; PHOSPHOTYROSINE; PLECKSTRIN;

ARTICLE; CELL PROTECTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY TEST; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CELL LINE, TUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; NEURONS; NF-KAPPA B; OXIDATIVE STRESS; PC12 CELLS; PEPTIDE FRAGMENTS; RATS; RECEPTORS, ADIPONECTIN;

EID: 84871660915     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052354     Document Type: Article

References (85)

1. Querfurth HW, LaFerla FM, (2010) Mechanism of disease: Alzheimer's Disease. N Engl J Med 362(4): 329-344.
2. Selkoe DJ, (1991) The molecular pathology of Alzheimer's disease. Neuron 6(4): 487-498.
3. Selkoe DJ, (2002) Alzheimer's disease is a synaptic failure. Science 298(5594): 789-791.
4. Selkoe DJ, Schenk D, (2003) Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol 43: 545-584.
5. Hardy J, Selkoe DJ, (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580): 353-356.
6. Alzheimer A, (1907) Über eine eigenartige Erkrankung der Hirnrinde. Centralblatt fur Nervenheilkunde Psychiatrie 30: 177-179.
7. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300(5618): 486-489.
8. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, et al. (1996) Correlative memory deficits; Aβ elevation, and amyloid plaques in transgenic mice. Science 274(5284): 99-102.
9. Walsh DM, Selkoe DJ, (2007) Aβ oligomers- a decade of discovery. J. Neurochem 101(5): 1172-1184.
10. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, et al. (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27(11): 2866-2875.
11. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008) Amyloid-β protein dimmers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14(8): 837-842.
12. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, et al. (2002) Naturally secreted oligomers of amyloid beta-protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880): 535-539.
13. Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, et al. (2005) Soluble β-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci 25(48): 11061-11070.
14. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, et al. (2006) AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52(5): 831-843.
15. Arispe N, Rojas E, Pollard H, (1993) Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci USA 90(2): 567-71.
16. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT, (2002) Neurodegenerative disease: Amyloid pores from pathogenic mutations. Nature 418(6895): 291.
17. Jones A, Kulozik P, Ostertag A, Herzig S, (2009) Common pathological processes and transcriptional pathways in Alzheimer's disease and type 2 diabetes. Journal of Alzheimer's Disease 16(4): 787-808.
18. Hoyer S, Muller D, Plaschke K (1994) Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism. J Neural Transm Suppl 44: 259-268.
19. Zhao W, Chen H, Xu H, Moore E, Meiri N, et al. (1999) Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem 274(49): 34893-34902.
20. Craft S, Watson GS, (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3(3): 169-178.
21. de a Monte SM, (2009) Insulin resistance and Alzheimer's disease. BMB Rep 42(8): 475-481.
22. McGeer PL, Rogers J, McGeer EG (2006) Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis 9(3 Suppl): 271-276.
23. Britschgi M, Wyss-Coray T, (2007) Immune cells may fend off Alzhimer disease. Nat Med 13(4): 408-409.
24. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT, (2010) Inflammation and Alzheimer's disease. Arch Pharm Res 33(10): 1539-1556.
25. Crouch PJ, Blake R, Duce JA, Ciccotosto GD, Li QX, et al. (2005) Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta-42. J Neurosci 25(3): 672-679.
26. Moreira PI, Duarte AI, Santos MS, Rego AC, Oliveira CR, (2009) An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. Journal of Alzheimer's Disease 16(4): 741-761.
27. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, et al. (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53(9): 1937-1942.
28. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, et al. (2004) The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292(18): 2237-2242.
29. Yaffe K, Haan M, Blackwell T, Cherkasova E, Whitmer RA, et al. (2007) Metabolic syndrome and cognitive decline in elderly Latinos: findings from the Sacramento Area Latino Study of Aging study. J Am Geriatr Soc 55(5): 758-762.
30. de la Monte SM, Tong M, Lester-Coll N, Plater M, Wands JR, (2006) Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis 10(1): 89-109.
31. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, et al. (2010) Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 107(15): 7036-7041.
32. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, et al. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116(7): 1784-1792.
33. Oh DK, Ciaraldi T, Henry RR, (2007) Adiponectin in health and disease. Diabetes Obes Metab 9(3): 282-289.
34. Hu E, Liang P, Spiegelman BM, (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271(18): 10697-10703.
35. Lam KS, Xu A, (2005) Adiponectin: protection of the endothelium. Curr Diab Rep 5(4): 254-259.
36. Schnabel R, Messow CM, Lubos E, Espinola-Klein C, Rupprecht HJ, et al. (2008) Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur Heart J 29(5): 649-657.
37. Wang Y, Lam KS, Yau MH, Xu A, (2008) Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 409(3): 623-633.
38. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, et al. (2006) APPL1 binds to adiponectin receptors and mediates adiponectin signaling and function. Nature Cell Biology 8(5): 516-523.
39. Citron M, Ottersdorf T, Haass C, McConlogue L, Hung AY, et al. (1992) Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β protein production. Nature 360(6405): 672-674.
40. Cai XD, Golde TE, Younkin SG, (1993) Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science 259(5094): 514-516.
41. Martin BL, Schrader-Fischer G, Busciglio J, Duke M, Paganetti P, et al. (1995) Intracellular accumulation of β-amyloid in cells expressing the Swedish mutant amyloid precursor protein. J Biol Chem 270(45): 26727-26730.
42. Zhong Z, Quon D, Higgins LS, Higaki J, Cordell B, (1994) Increased amyloid production from aberrant beta-amyloid precursor proteins. J Biol Chem 269(16): 12179-12184.
43. LaFerla FM, Green KN, Oddo S, (2007) Intracellular amyloid-β in Alzheimer's disease. Nature Reviews Neuroscience 8(7): 499-509.
44. Marques CA, Keil U, Bonert A, Steiner B, Haass C, et al. (2003) Neurotoxic mechanisms caused by Alzheimer's disease-linked Swedish amyloid precursor protein mutation. J Biol Chem 278(30): 28294-28302.
45. Zhou L, Chan KH, Chu LW, Kwan JS, Song YQ, et al. (2012) Plasma amyloid-β oligomers level is a biomarker for Alzheimer's disease diagnosis. Biochemical and Biophysical Research Communications 423(4): 697-702.
46. Xu A, Yin S, Wong L, Chan KW, Lam KS, (2004) Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology 145(2): 487-494.
47. Cheng KKY, Lam KS, Wand Y, et al. (2007) Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes 56: 1387.
48. Jung TW, Lee JY, Shim WS, Kang ES, Kim JS, et al. (2006) Adiponectin protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity. Biochemical Pharmacology 72(5): 616-623.
49. Bonda DJ, Wang X, Perry G, Nunomura A, Tabaton M, et al. (2010) Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology 59(4-5): 290-294.
50. Cho DH, Nakamura T, Fang J, Cieplak P, Godzik A, et al. (2009) S-nitrosylation of Drp-1 mediates β-amyloid-related-mitochondrial fission and neuronal injury. Science 324(5923): 102-105.
51. Praticò D, (2008) Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends in Pharmacological Sciences 29(12): 609-615.
52. Praticò D, Uryu K, Leight S, Trojanoswki JQ, Lee VM, (2001) Increase lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21(12): 4183-4187.
53. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, et al. (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60(8): 759-767.
54. Spasić MR, Callaerts P, Norga KK, (2009) AMP-activated protein kinase (AMPK) molecular crossroad for metabolic control and survival of neurons. The Neuroscientist 15(4): 309-316.
55. Culmsee C, Monnig J, Kemp BE, Mattson MP, (2001) AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J Mol Neurosci 17(1): 45-58.
56. Thornton C, Bright NJ, Sastre M, Muckett PJ, Carling D, (2011) AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid β-peptide exposure. Biochem J 434(3): 503-512.
57. Vingtdeux V, Davies P, Dickson DW, Marambaud P, (2011) AMPK is abnormally activated in tangle- and pretangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol 121(3): 337-349.
58. Une K, Takei YA, Tomita N, Asamura T, Ohrui T, et al. (2010) Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer's disease. Eur J Neurol 18 (7): 1006-1009.
59. van Himbergen TM, Beiser AS, Ai M, Seshadri S, Otokozawa S, et al. (2012) Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease. Results from the Framingham Heart Study. Arch Neurol 69(5): 594-600.
60. Deepa SS, Dong LQ, (2009) APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab 296(1): E22-E26.
61. Dasgupta B, Milbrandt J, (2007) Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A 104(17): 7217-7222.
62. Ceddia RB, Somwar R, Maida A, Fang X, Bikopoulos G, et al. (2005) Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia 48(1): 132-139.
63. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, et al. (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 7(1): 63-80.
64. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, et al. (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8(3): 247-268.
65. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, et al. (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70(6): 440-448.
66. Mrak RE, (2009) Neuropathology and the neuroinflammation idea. Journal of Alzheimer's disease 18(3): 473-481.
67. McGeer EG, McGeer PL, (2010) Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. Journal of Alzheimer's disease 19(1): 355-361.
68. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, et al. (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer's disease. Proc Natl Acad Sci U S A 91(11): 4766-4770.
69. Yan SD, Chen X, Fu J, Chen M, Zhu H, et al. (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382(6593): 685-691.
70. Yan SD, Yan SF, Chen X, Fu J, Chen M, et al. (1995) Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med 1(7): 693-699.
71. Granic I, Dolga AM, Nijholt IM, van Dijk G, Eisel UL, (2009) Inflammation and NFκB in Alzheimer's disease and diabetes. Journal of Alzheimer's Disease 16(4): 809-821.
72. Terai K, Matsuo A, McGeer PL, (1996) Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res 735(1): 159-168.
73. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschimidt C, (1997) Transcription factor NF-kappa B is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci U S A 94(6): 2642-2647.
74. Boissière F, Hunot S, Faucheux B, Duyckaerts C, Hauw JJ, et al. (1997) Nuclear translocation of NF-kappa B in cholinergic neurons of patients with Alzheimer's disease. Neuroreport 8(13): 2849-2852.
75. Lukiw WJ, Bazan NG, (1998) Strong nuclear factor-kappa B DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex. J Neurosci Res 53(5): 583-592.
76. Chandrasekar B, Boylston WH, Venkatachalam K, Webster NJ, Prabhu SD, et al. (2008) Adiponectin blocks interleukin-18-mediated endothelial cell death via APPL1-dependent AMP-activated protein kinase (AMPK) activation and IKK/NF-κB/PTEN suppression. J Bio Chem 283(36): 24889-24898.
77. Manning BD, Cantley LC, (2007) AKT/PKB signaling: navigating downstream. Cell 129(7): 1261-1274.
78. Ojala J, Alafuzoff I, Herukka SK, van Groen T, Tanila H, et al. (2007) Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients. Neurobiology of Aging 30(2): 198-209.
79. Bossù P, Ciaramella A, Salani F, Bizzoni F, Varsi E, et al. (2008) Interleukin-18 produced by peripheral blood cells is increased in Alzheimer's disease and correlates with cognitive impairment. Brain Behavior and Immunity 22(4): 487-492.
80. Chen B, Liao WQ, Xu N, Xu H, Wen JY, et al. (2009) Adiponectin protects against cerebral ischemia-reperfusion injury through anti-inflammatory action. Brain Research 1273: 129-137.
81. Jung TW, Lee JY, Shim WS, Kang ES, Kim JS, et al. (2006) Adiponectin protects human neuroblastoma SH-SY5Y cells against MPP+-induced cytotoxicity. Biochemical and Biophysical Research Communication 343(2): 564-570.
82. Jeon BT, Shin HJ, Kim JB, Kim YK, Lee DH, et al. (2009) Adiponectin protects hippocampal neurons against kainic acid-induced excitotoxicity. Brain Research Reviews 61(2): 81-88.
83. Psilopanagioti A, Papadaki H, Kranioti EF, Alexandrides TK, Varakis JN, (2009) Expression of adiponectin and adiponectin receptor in human pituitary gland and brain. Neuroendocrinology 89(1): 38-47.
84. Greco SJ, Sarkar S, Johnston JM, Tezapsidis N, (2009) Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem Biophys Res Commun 380(1): 98-104.
85. Greco SJ, Bryan KJ, Sarkar S, Zhu X, Smith MA, et al. (2010) Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. Journal of Alzheimer's Disease 19(4): 1155-1167.